Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744301 | 1.00 | SGPL1 (0.78) | SGPL1SMO | |
| SCHEMBL20740314 | 1.00 | SGPL1 (0.78) | SGPL1SMO | |
| SCHEMBL20740316 | 0.93 | SGPL1 (0.79) | SGPL1SMO | |
| SCHEMBL20740315 | 0.93 | SGPL1 (0.79) | SGPL1SMO | |
| SCHEMBL3607777 | 0.82 | SGPL1 (0.61) | SGPL1SMO | |
| SCHEMBL20740311 | 0.82 | SGPL1 (0.61) | SGPL1SMO | |
| SCHEMBL3596417 | 0.81 | SGPL1 (1.00) | SGPL1SMO | |
| SCHEMBL3596414 | 0.81 | SGPL1 (1.00) | SGPL1SMO | |
| SCHEMBL3607834 | 0.81 | SGPL1 (1.00) | SGPL1SMO | |
| SCHEMBL13444970 | 0.79 | SMO (1.00) | SGPL1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | claimed |
| CN-111432815-A | Enhancing cancer treatment efficacy via sphingosine-1-phosphate pathway | AC生物科学公司 | 2020-07-17 | — | — | CN | claimed |
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | AC BIOSCIENCE (CH) | 2023-12-26 | — | — | US | disclosed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | disclosed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | disclosed |
| CN-111432815-A | Enhancing cancer treatment efficacy via sphingosine-1-phosphate pathway | AC生物科学公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3668506-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BioScience (CH) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | disclosed |
| EP-3443986-A1 | ENHANCEMENT OF CHEMOTHERAPY EFFICIENCY BY SPHINGOSINE-1-PHOSPHATE | AC BioScience (CH) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | SPHK1, S1PR1, S1PR2 | SGPL1 7/4885SMO 3153/4885 |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | SPHK1, S1PR1, S1PR2 | SGPL1 7/4885SMO 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.